Plasma iron and ferritin concentrations in aplastic anemia patients treated long term with EPAG. (A) Dose of EPAG administered and iron concentrations in 2 MAA patients from protocol initiation through current follow-up. EPAG was discontinued per protocol criteria for robust hematologic response on day 299 in patient 1 and on day 371 in patient 2. Subsequently, both patients experienced declining blood cell counts, and EPAG was re-initiated at the last effective dose per protocol. After achieving a second robust response, the EPAG dose was slowly tapered in both patients. Neither patient received concomitant iron chelators or red blood cell transfusions. (B) Ferritin levels in MAA patients with an EPAG treatment duration of at least 4 months. No patient received red blood cell transfusions, therapeutic phlebotomy, or pharmacological chelation during the time intervals graphed. The black circles indicate the time point of EPAG discontinuation. (C) Comparison of ferritin levels pretreatment and after EPAG discontinuation (first measurement after EPAG discontinuation corresponds to black circles in panel B) in 6 MAA patients with prolonged EPAG treatment and ferritin measurements available at follow-up. P value was calculated on the basis of paired Student t tests. **P = .005.